Ovarian Cancer News

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms (May 3, 2017)

A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer.  Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis... Continue Reading

Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial (April 25, 2017)

UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering... Continue Reading

Niraparib Approved for Ovarian Cancer Maintenance Treatment (April 3, 2017)

Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based... Continue Reading

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response? (March 6, 2017)

A clinical study with Keytruda (pembrolizumab) in a novel untried combination is the first ovarian cancer clinical trial to incorporate gut flora analysis.  Dr. Emese Zsiros, the study’s Principal Investigator, explains a new, unique clinical trial... Continue Reading

Chemo-brain Among Women with Breast Cancer is Very Common (February 28, 2017)

The largest study to date of a condition known as “chemo-brain” shows that women with breast cancer report it’s a substantial problem after chemotherapy for as long as six months after treatment, according to investigators at the Wilmot Cancer Institute. Scientists... Continue Reading

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (December 20, 2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

Latest Ovarian Cancer News By Stage


Recurrent Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (July 13, 2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed... Continue Reading

More Recurrent Ovarian Cancer

Screening/Prevention Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

FDA Warns Against Ovarian Cancer Screening Tests (October 6, 2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Personalized Screening Test for Ovarian Cancer Potentially Game-Changing, says GlobalData (May 18, 2015)

   LONDON, UK (GlobalData), 12 May 2015 – The encouraging recent results of a 14-year study by the UK Collaborative Trial of Ovarian Cancer Screening could herald a radical departure from the approach established by other screening tests for... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

More Screening/Prevention Ovarian Cancer

Stage I Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Intraperitoneal Chemotherapy Underused in Ovarian Cancer (September 28, 2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

More Stage I Ovarian Cancer

Stage II-IV Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (December 20, 2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

More Stage II-IV Ovarian Cancer